TABLE 1.

Description of all datasets collected in this study.

Usage	Dataset	Regimen	ER-negative sample size	pCR	RD	With DRFS information
Training	GSE20194 Popovici et al. (2010)	T-FA(E)Ca	114	46	68	no
	GSE20271 Tabchy et al. (2010)	T-FA(E)C	79	19	60	no
	MDA133 Hess et al. (2006)	T-FAC	51	27	24	no
	GSE41998 Horak et al. (2013)	T-ACb	48	29	19d	no
Validation	GSE25055 Hatzis et al. (2011)	T-AC;TAc	129	45	84	yes
	GSE25065 Hatzis et al. (2011)	TA	68	23	45	yes

^aT-FA(E)C paclitaxel (T) followed by fluorouracil (F), doxorubicin (A) [or epirubicin (E)] and cyclophosphamide (C). ^bT-AC doxorubicin (A) and cyclophosphamide (C) followed by paclitaxel (T). ^cTA taxane (T) and anthracycline (A) based regimens. ^dPD and SD samples representing tumor residuals screened from RD samples.